Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease

Inclusion Criteria: To be eligible for inclusion in this clinical study, all of the following criteria must be met: 1. Clinically confirmed diagnosis of primary PD (in accordance with the 2016 Chinese Diagnostic Criteria for Parkinson's Disease or the 2015 MDS Clinical Diagnostic Criteria for primary PD); 2. Age 40-65 years (inclusive) at screening, either sex; 3. Disease duration ≤ 5 years; 4. Hoehn \& Yahr stage ≤ 2 in the "off" state. Exclusion Criteria: Exclusion Criteria 1. Atypical or secondary parkinsonian syndromes (e.g., Parkinson-plus syndromes, hereditary parkinsonism, drug-induced parkinsonism, etc.). 2. Contra-indications to surgery, or any prior intracranial procedure such as deep-brain stimulation, pallidotomy, or other extrapyramidal surgery, or any other neurosurgical intervention deemed by the investigator to interfere with study participation. 3. Previous neuroimaging revealing structural brain abnormalities, cerebral vascular malformations, intracranial tumors, risk of intracranial hemorrhage, traumatic brain injury, or other significant findings. 4. Mini-Mental State Examination (MMSE) score \< 24. 5. Patient Health Questionnaire-9 (PHQ-9) score ≥ 16. 6. Abnormal hepatic or renal function: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 1.5 × upper limit of normal (ULN), or serum creatinine (Cr) \> 1.5 × ULN. 7. Coagulation disorders or current use of anticoagulants. 8. Positive screening for infectious diseases: * Hepatitis B surface antigen (HBsAg) or Hepatitis B virus DNA (HBV-DNA) positive; * Hepatitis C virus RNA (HCV-RNA) positive; * Human immunodeficiency virus (HIV) positive; * Positive syphilis serology. 9. Currently receiving antiviral therapy for hepatitis B or C.